相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN gamma secretion
Bharat K. R. Chaganty et al.
CANCER LETTERS (2018)
Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Sofie Ellebaek Pollmann et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solidtumors
Takashi Kojima et al.
CANCER SCIENCE (2018)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
Yotam Bar-On et al.
NATURE MEDICINE (2018)
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors
Maicol Mancini et al.
EMBO MOLECULAR MEDICINE (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes
Yongfeng Fan et al.
PLOS ONE (2017)
Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors
Thomas Tuxen Poulsen et al.
CLINICAL CANCER RESEARCH (2017)
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18
Silvia Carvalho et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease
Davide Corti et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Two-mAb cocktail protects macaques against the Makona variant of Ebola virus
Xiangguo Qiu et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The use of combinations of monoclonal antibodies in clinical oncology
Linda M. Henricks et al.
CANCER TREATMENT REVIEWS (2015)
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Helle J. Jacobsen et al.
CLINICAL CANCER RESEARCH (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection
Kristen E. Pascal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough
Annalee W. Nguyen et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the THERAPY phase 1-2 trial
Eric Assenat et al.
ONCOTARGET (2015)
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
Shihao Chen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A
S. U. Nayak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem et al.
CLINICAL CANCER RESEARCH (2014)
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Mari Iida et al.
MOLECULAR CANCER (2014)
Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression
Sandra Heskamp et al.
MOLECULAR PHARMACEUTICS (2014)
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
Gaeelle Thomas et al.
ONCOTARGET (2014)
Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors
Christopher Hanyoung Lieu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Zhiqiang Guo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Ruth Maron et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Recombinant antibody mixtures: Production strategies and cost considerations
Soren K. Rasmussen et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
Tadeusz Robak et al.
BLOOD (2012)
Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies
Andre J. Marozsan et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Capturing the Natural Diversity of the Human Antibody Response against Vaccinia Virus
Johan Lantto et al.
JOURNAL OF VIROLOGY (2011)
Advances in the production and downstream processing of antibodies
John H. Chon et al.
NEW BIOTECHNOLOGY (2011)
Generation of Stable Cell Clones Expressing Mixtures of Human Antibodies
John de Kruif et al.
BIOTECHNOLOGY AND BIOENGINEERING (2010)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
Tsipi Ben-Kasus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas
Christel Larbouret et al.
CLINICAL CANCER RESEARCH (2007)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
Sandra J. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Production of target-specific recombinant human polyclonal antibodies in mammalian cells
Finn C. Wiberg et al.
BIOTECHNOLOGY AND BIOENGINEERING (2006)
Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants
ABH Bakker et al.
JOURNAL OF VIROLOGY (2005)
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
LM Friedman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties
E Galun et al.
HEPATOLOGY (2002)
分享论文
